Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|December 15, 2019
- Pharmaceutical Technology-12-15-2019
- Volume 2019 eBook
- Issue 3
Warning Letters Signal Steps to Compliance
Author(s)Rita C. Peters
Warning letters tell the tale of missteps by drug companies and offer a path to compliance for quality teams that monitor these enforcement actions.
Advertisement
While the number of warning letters issued by FDA has declined slightly, recurrent violations include poorly maintained equipment and facilities, insufficient cleaning validation, inadequate written procedures for quality testing, and inadequate controls over data and computer systems. Effective, ongoing monitoring programs-for regulatory agency enforcement actions and pharmacopoeia updates-are essential for bio/pharma compliance.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook, December 2019
December 2019
Pages: 4–5
Citation
When referring to this article, please cite it as R. Peters, “Warning Letters Signal Steps to Compliance," Pharmaceutical Technology Regulatory Sourcebook eBook (December 2019).
Articles in this issue
almost 7 years ago
Revision Process for Global/National Pharmacopoeias (eBook)almost 7 years ago
Regulatory and Standard Setting Organizationsalmost 7 years ago
Resources, Guidelines, and Guidance Documentsalmost 7 years ago
Design of Experiments Gains Ground in Biopharma Developmentalmost 7 years ago
Quality Risk Management Plans Create Effective Quality Systemsalmost 7 years ago
Moving from Compliance to QualityAdvertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement